These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 14655062

  • 21. Role of cystic fluid in diagnosis of the pancreatic cystadenoma and cystadenocarcinoma.
    Wu H, Yan LN, Cheng NS, Zhang YG, Ker CG.
    Hepatogastroenterology; 2007; 54(79):1915-8. PubMed ID: 18251127
    [Abstract] [Full Text] [Related]

  • 22. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease.
    Waanders E, van Keimpema L, Brouwer JT, van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP.
    Liver Int; 2009 Oct; 29(9):1389-95. PubMed ID: 19515221
    [Abstract] [Full Text] [Related]

  • 23. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
    Kim HJ, Lee KW, Kim YJ, Oh DY, Kim JH, Im SA, Lee JS.
    Acta Oncol; 2009 Oct; 48(3):385-90. PubMed ID: 18855156
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Biliary carcinoembryonic antigen, non-specific cross-reacting antigen and biliary glycoprotein--their analysis and clinical aspects].
    Yano Y.
    Nihon Geka Gakkai Zasshi; 1986 Nov; 87(11):1432-42. PubMed ID: 3537682
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R, Meyer-Wyss B, Herzog U, Tondelli P.
    Schweiz Med Wochenschr; 1999 Jan 23; 129(3):77-9. PubMed ID: 10065510
    [Abstract] [Full Text] [Related]

  • 31. Biliary carcinoembryonic antigen levels can predict metachronous liver metastasis of colorectal cancer.
    Ishida H, Yoshinaga K, Gonda T, Ando M, Hojo I, Fukunari H, Iwama T, Mishima Y.
    Anticancer Res; 2000 Jan 23; 20(1B):523-6. PubMed ID: 10769718
    [Abstract] [Full Text] [Related]

  • 32. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW, Jiang B, Han CZ, Jing JX.
    Zhonghua Zhong Liu Za Zhi; 2005 May 23; 27(5):286-8. PubMed ID: 15996321
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J, Emparan C, Hernandez CA, Sulkowski U, Dietl KH, Menzel J, Wolters H, Glodny B, Senninger N.
    Anticancer Res; 2000 May 23; 20(6D):4941-7. PubMed ID: 11326643
    [Abstract] [Full Text] [Related]

  • 36. Clinicopathological features of malignant intraductal papillary mucinous tumors of the pancreas: the differential diagnosis from benign entities.
    Kawai M, Uchiyama K, Tani M, Onishi H, Kinoshita H, Ueno M, Hama T, Yamaue H.
    Arch Surg; 2004 Feb 23; 139(2):188-92. PubMed ID: 14769579
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.